Mebendazole

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Retrieved on: 
Tuesday, January 16, 2024
Artificial intelligence, Glioblastoma, Mebendazole, Cancer, Solubility, Bullfrog, Prodrug, Machine learning, Patent, Pharmaceutical industry

2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases.

Key Points: 
  • 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases.
  • This follows the July 2023 announcement of the issuance of U.S. Patent No.
  • 11,712,435 for this invention ( link ), with issuance of patents expected in additional territories in the future.
  • "This patent grant further strengthens intellectual property protection of this key asset in our pipeline," said Vin Singh, founder and CEO of BullFrog AI.

BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma

Retrieved on: 
Tuesday, September 26, 2023
Mouse, Animal, Survival, Cancer, Solubility, Glioblastoma, Machine learning, Artificial intelligence, Mebendazole, Bullfrog, Pharmaceutical industry

GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for the treatment of glioblastoma.

Key Points: 
  • GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for the treatment of glioblastoma.
  • The study assessed the relative efficacy of BF-222, a novel formulation of mebendazole that has been evaluated in clinical trials, and BF-223, a novel prodrug of mebendazole with improved solubility and bioavailability relative to BF-222, compared with placebo in mice that had been implanted with tumor cells as a model for human glioblastoma.
  • “This is the first study to demonstrate that BF-223, a novel mebendazole prodrug, has anti-cancer activity in animals,” said Vin Singh, Chairman and CEO of BullFrog AI.
  • We are currently pursuing partnering opportunities for BF-222 and BF-223 with pharmaceutical companies and are confident that these data will assist in that effort.”

BullFrog AI Announces Issuance of U.S. Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Retrieved on: 
Tuesday, July 25, 2023
Patent, Cancer, Solubility, Mebendazole, Prodrug, Glioblastoma, Johns Hopkins University, Machine learning, Medicine, Artificial intelligence, Bullfrog, Pharmaceutical industry

11,712,435 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases.

Key Points: 
  • 11,712,435 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases.
  • 11,712,435 represents the first issued patent resulting from intellectual property BullFrog AI licensed from Johns Hopkins University in October 2022.
  • BullFrog AI’s exclusive, worldwide, royalty-bearing license includes the rights to commercialize prodrugs of mebendazole that demonstrate improved solubility and bioavailability relative to the parent compound.
  • "This patent grant further strengthens intellectual property protection of our carefully curated and strategically acquired licensed product portfolio," said Vin Singh, founder and CEO of BullFrog AI.

BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets

Retrieved on: 
Thursday, April 20, 2023
Glioblastoma, Partnership, Sage, Sage Group, Cancer, Brain, JV, Regenerative medicine, JHU, Machine learning, Medicine, Mebendazole, Bullfrog, Medical device, Pharmaceutical industry

The engagement will focus on seeking joint venture (JV) opportunities to further advance BullFrog AI’s Phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as well as the Company’s preclinical prodrug asset.

Key Points: 
  • The engagement will focus on seeking joint venture (JV) opportunities to further advance BullFrog AI’s Phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as well as the Company’s preclinical prodrug asset.
  • The partnership will give BullFrog AI access to the Sage Group’s clinical and regulatory expertise, capital resources, and network of contacts, including innovators and large pharma.
  • "Glioblastoma is one of the deadliest forms of cancer, with a five-year survival rate of less than seven percent,” said BullFrog AI’s founder and CEO, Vin Singh.
  • BullFrog AI has previously announced the grant of exclusive licenses from JHU for a novel formulation of mebendazole that has been evaluated in two clinical trials for glioblastoma, and for a novel prodrug of mebendazole with improved bioavailability.

BullFrog AI Announces Licensing Agreement with Johns Hopkins University for Oncology Asset

Retrieved on: 
Tuesday, April 18, 2023
Mebendazole, Johns Hopkins, Medicine, Johns Hopkins University, Patent, Bullfrog, Machine learning, Solubility, Glioblastoma, Pharmaceutical industry

GAITHERSBURG, Md., April 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole.

Key Points: 
  • GAITHERSBURG, Md., April 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole.
  • The world-wide, royalty-bearing license includes the rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability relative to the parent compound.
  • The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications.
  • We look forward to working with strategic partners to advance the development and monetize this promising asset for the treatment of glioblastoma and possibly additional oncology indications."

Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature

Retrieved on: 
Wednesday, March 15, 2023
Science, Biotechnology, Research, Pharmaceutical, Environment, Health, Climate Change, Clinical Trials, CD3, Johnson & Johnson, Lead, Duke–NUS Medical School, Emerging Pathogens Institute, Heidelberg University, NS4B, Tropical medicine, Hospital, Trial of the century, Janssen Pharmaceuticals, Walter Reed Army Institute of Research, NS3, Global health, Viral, Kigali Declaration on Neglected Tropical Diseases, Infection, Aix-Marseille University, Fever Dream, Neglected tropical diseases, University, Artificial intelligence, Mebendazole, Janssen, Mouse, Risk, Drug design, Hope, Dengue fever, Biomedical Primate Research Centre, Leprosy, Society, Hygiene, Climate change, UTMB, Disease, Incidence, Dengue virus, Therapy, Pharmaceutical industry, Vaccine, Nature, Virology

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice.

Key Points: 
  • The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice.
  • These findings build on research published in Nature in 2021 that first identified the novel mechanism of action from the same chemical series as JNJ-1802.
  • In addition to developing JNJ-1802, Johnson & Johnson is working to holistically strengthen R&D for dengue, including through novel R&D approaches and leveraging emerging technology.
  • You can learn more about Johnson & Johnson’s efforts to beat NTDs, including dengue, by visiting JNJ.com/NTDs .